Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy in patients with biliary tract carcinomas - A Nordic phase II study
2014-002798-12Phase 2Terminated
- Sponsor
- University Hospital Odense
- Start
- Jul 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin and oxaliplatin in biliary cancer, gallbladder cancer, intrahepatic cholangiocarcinoma (ICC) and 2 more, sponsored by University Hospital Odense. Primary endpoint: 2-year overall survival. Started Jul 2014; status: terminated.
02
Drugs
gemcitabinecisplatinoxaliplatin
03
Conditions
biliary cancergallbladder cancerintrahepatic cholangiocarcinoma (ICC)hilar cholangiocarcinoma (HC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2014-002798-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002798-12.